Lexaria Bioscience (LEXX) Total Current Liabilities (2011 - 2026)

Lexaria Bioscience has disclosed Total Current Liabilities across 16 years of filings, most recently posting $214671.0 for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $214671.0, down 88.22% year-over-year; the trailing twelve-month figure through Feb 2026 was $214671.0 (down 88.22% YoY), and the FY2025 annual result was $1.5 million, up 35.84% from the prior year.
• Total Current Liabilities came in at $214671.0 for Q1 2026 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.8 million in Q1 2025 to a low of $81717.0 in Q1 2024.
• The 5-year median for Total Current Liabilities is $267735.0 (2023), against an average of $625259.7.
• Across the five-year window, Total Current Liabilities surged 2130.16% in 2025 and sank 88.22% in 2026, its largest moves.
• Lexaria Bioscience's Total Current Liabilities stood at $281520.0 in 2022, then plunged by 55.77% to $124523.0 in 2023, then jumped by 139.15% to $297798.0 in 2024, then soared by 389.1% to $1.5 million in 2025, then plunged by 85.26% to $214671.0 in 2026.
• The last three Total Current Liabilities figures came in at $214671.0 (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.